Completed PHASE2 INTERVENTIONAL 1-arm NCT03113851

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

Observation of Abscopal Effect of Radiation in Combination With rhGM-CSF for Patients With Metastatic Non-small Cell Lung Cancer

Sponsor: Peking University Cancer Hospital & Institute

Conditions Lung Cancer Metastatic

Interventions Radiotherapy rhGM-CSF

Updated 8 times since 2017 Last updated: Jun 12, 2023 Started: Aug 14, 2017 Primary completion: Aug 14, 2018 Completion: Oct 14, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Cancer Metastatic, this trial is completed. The trial is conducted by Peking University Cancer Hospital & Institute and has accumulated 8 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Nov 2022 — Jul 2023 [monthly]

Unknown Status PHASE2
Jan 2021 — Nov 2022 [monthly]

Unknown Status PHASE2

▶ Show 3 earlier versions

May 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — May 2019 [monthly]

Recruiting PHASE2
May 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University Cancer Hospital & Institute

Data source: Peking University Cancer Hospital & Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China